Novartis Pharma Schweiz AG

3 articles about Novartis Pharma Schweiz AG

• Premark Pharma Licenses Worldwide Rights to PMP2207 for Ophthalmic Indications and Targets a First Regulatory Approval for Blepharitis

  6/25/2019

  Premark Pharma announced the completion of a licensing deal with Novartis Pharma AG, granting Premark exclusive worldwide rights to develop and commercialise PMP2207, an ophthalmic ointment formulation, as a potential treatment for blepharitis.

• 350 New Jobs Planned For Novartis Vaccines and Diagnostics

  7/19/2006

• Novartis Enters "Good Cholesterol" Battle

  7/12/2005